Literature DB >> 35317507

Optic Neuritis due to Use of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Case Report.

Türkan Acar1, Halil Alper Eryilmaz1, Bilgehan Atilgan Acar1, Ertuğrul Güçlü2, Oğuz Karabay2.   

Abstract

Neuroophthalmic involvement may occur in people infected with primary human immunodeficiency virus (HIV) due to the infection itself, opportunistic infections, malignancy or due to vascular causes. However, treatment-related optic neuropathy may be considered in patients receiving Antiretroviral therapy (ART), without an identified etiological cause, despite all examinations. In this case report, a near-complete recovery was observed in vision loss of a patient, whose 4-month treatment regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) was replaced with a combination of tenofovir disoproxil + emtricitabine and lopinavir+ritonavir due to the development of optic neuritis. Recognition of the present symptoms rapidly and the implementation of the necessary change is extremely important for preventing permanent damage in these patients. Copyright:
© 2022 Turkish Neuropsychiatric Society.

Entities:  

Keywords:  HIV; antiretroviral therapy; optic neuritis

Year:  2022        PMID: 35317507      PMCID: PMC8895810          DOI: 10.29399/npa.26137

Source DB:  PubMed          Journal:  Noro Psikiyatr Ars        ISSN: 1300-0667            Impact factor:   1.339


  15 in total

1.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults.

Authors:  Peter J Ruane; Edwin DeJesus; Daniel Berger; Martin Markowitz; U Fritz Bredeek; Christian Callebaut; Lijie Zhong; Srini Ramanathan; Martin S Rhee; Marshall W Fordyce; Kitty Yale
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

Review 2.  Pathways to neuronal injury and apoptosis in HIV-associated dementia.

Authors:  M Kaul; G A Garden; S A Lipton
Journal:  Nature       Date:  2001-04-19       Impact factor: 49.962

Review 3.  Ophthalmic adverse drug reactions to systemic drugs: a systematic review.

Authors:  Ana Miguel; Filipe Henriques; Luís Filipe Azevedo; Altamiro Costa Pereira
Journal:  Pharmacoepidemiol Drug Saf       Date:  2014-01-27       Impact factor: 2.890

4.  Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?

Authors:  Agostino Riva; Alessandro Invernizzi; Chiara Resnati; Valeria Micheli; Dario Cattaneo; Cristina Gervasoni
Journal:  Antivir Ther       Date:  2016-06-22

Review 5.  Drug-induced corneal complications.

Authors:  David A Hollander; Anthony J Aldave
Journal:  Curr Opin Ophthalmol       Date:  2004-12       Impact factor: 3.761

Review 6.  Monocyte/macrophages and their role in HIV neuropathogenesis.

Authors:  Tricia H Burdo; Andrew Lackner; Kenneth C Williams
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

7.  Neuro-ophthalmic findings in progressive multifocal leukoencephalopathy.

Authors:  F Wein; G S Francis; M S Gans; W E Connolly; M N Burnier
Journal:  Can J Ophthalmol       Date:  1998-08       Impact factor: 1.882

8.  Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.

Authors:  Gustaf Ulfhammer; Arvid Edén; Åsa Mellgren; Dietmar Fuchs; Henrik Zetterberg; Lars Hagberg; Staffan Nilsson; Aylin Yilmaz; Magnus Gisslén
Journal:  AIDS       Date:  2018-09-24       Impact factor: 4.177

Review 9.  Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies.

Authors:  Valerio Carelli; Fred N Ross-Cisneros; Alfredo A Sadun
Journal:  Neurochem Int       Date:  2002-05       Impact factor: 3.921

10.  Neurologic signs and symptoms frequently manifest in acute HIV infection.

Authors:  Joanna Hellmuth; James L K Fletcher; Victor Valcour; Eugène Kroon; Jintanat Ananworanich; Jintana Intasan; Sukalaya Lerdlum; Jared Narvid; Mantana Pothisri; Isabel Allen; Shelly J Krebs; Bonnie Slike; Peeriya Prueksakaew; Linda L Jagodzinski; Suwanna Puttamaswin; Nittaya Phanuphak; Serena Spudich
Journal:  Neurology       Date:  2016-06-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.